El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis
- B. Brooks, Robert G. Miller, M. Swash, T. Munsat
- Medicine, PsychologyAmyotrophic Lateral Sclerosis and other Motor…
- 1 January 2000
The criteria described below represent the result of a three-day workshop, convened at Airlie Conference Center, Warrenton, Virginia on 2–4 April, 1998 by the World Federation of Neurology Research Committee on Motor Neuron Diseases, and are placed on the WFN ALS website.
Mutations in UBQLN2 cause dominant X-linked juvenile and adult onset ALS and ALS/dementia
- H. Deng, Wenjie Chen, T. Siddique
- BiologyNature
- 4 August 2011
Findings link abnormalities in ubiquilin 2 to defects in the protein degradation pathway, abnormal protein aggregation and neurodegeneration, indicating a common pathogenic mechanism that can be exploited for therapeutic intervention.
El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
- B. Brooks
- PsychologyJournal of Neurological Sciences
- 1 July 1994
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple…
- K. Johnson, B. Brooks, R. Schiffer
- MedicineNeurology
- 1995
Copolymer 1 (Copaxone) was studied in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis and significantly more patients receiving copolym 1 were found to have improved and more receiving placebo worsened.
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
- K. Johnson, B. Brooks, J. Wolinsky
- Medicine, PsychologyNeurology
- 1 July 1995
It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion.
Controversies and priorities in amyotrophic lateral sclerosis
- M. Turner, O. Hardiman, M. Kiernan
- BiologyLancet Neurology
- 1 March 2013
Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia
- J. Yan, H. Deng, T. Siddique
- Biology, MedicineNeurology
- 31 August 2010
FUS gene mutations are not an uncommon cause in patients with FALS from diverse genetic backgrounds, and have a prevalence of 5.6% in non-SOD1 and non-TARDBP FALS, and ∼4.79% in all FALS.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
- K. Johnson, B. Brooks, J. Wolinsky
- Psychology, MedicineNeurology
- 1 March 1998
The clinical benefit of glatiramer acetate for both the relapse rate and for neurologic disability was sustained at the end of the extension trial.
Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study
- C. Konrad, H. Henningsen, B. Brooks
- Biology, PsychologyExperimental Brain Research
- 24 January 2002
The results demonstrate a general pattern of functional changes after motor neuron degeneration and support the concept of a structurally parallel and functionally specialized organization of voluntary motor control.
Practice parameter: The care of the patient with amyotrophic lateral sclerosis (An evidence‐based review)
- R.G. Miller, J. A. Rosenberg, E. Oppenheimer
- MedicineMuscle and Nerve
- 1 August 1999
This information is current as of August 7, 2006 and can be found on the World Wide Web at: http://www.neurology.org/cgi/content/full/52/7/1311.
...
...